Aligos Therapeutics (ALGS) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Company overview and pipeline

• Founded in 2018 to develop therapies for liver and viral diseases, with a pipeline including CAM-E for hepatitis B, Aligos 009 for MASH, and a pan-coronavirus inhibitor.

• CAM-E targets chronic hepatitis B, aiming to surpass standard NUCs in efficacy.

• Aligos 009 is designed for MASH, with higher potency and improved pharmacokinetics compared to competitors.

• The pan-coronavirus inhibitor is being developed as a ritonavir-free COVID therapy.

Hepatitis B (CAM-E) program

• CAM-E uses dual mechanisms to lower viral load and reduce key antigens, targeting the cccDNA reservoir.

• Phase 1 monotherapy data showed 100% E-negative and 60% E-positive patients below quantification at 48 weeks, with all E-positives reaching this at 84 weeks.

• CAM-E demonstrated superior viral suppression compared to NUCs, with no added benefit from combination therapy.

• Phase 2 will directly compare CAM-E to NUCs in a superiority design, with a primary endpoint at 48 weeks.

• Plans include exploring combination therapies, starting with a study in China combining CAM-E with pegylated interferon.

MASH (Aligos 009) program

• Aligos 009 shows up to 50-fold higher potency and improved PK over Madrigal's compound.

• Phase 2a HALO study showed a 46% placebo-adjusted median fat reduction and favorable side effect profile.

• Next steps include a phase 2b study to confirm safety and evaluate histological improvement, with up to 70% of patients achieving >30% fat reduction.

• Active discussions with potential partners are ongoing.